HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Anesthesia · Monitoring Therapeutic Area Assessment

Intelligence report

Intelligence Report · ~15 min read

Anesthesia · Monitoring Therapeutic Area Assessment

24 signals · 6 insights · 89 regulatory precedents

Type

Therapeutic Area Assessment

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 61%

Evidence

119 items

Sources

2

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Therapeutic area assessment for Anesthesia · Monitoring integrates 24 signals, 6 executive insights, and 89 regulatory precedents from the Humanexa intelligence graph. 1 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. signalJul 17, 2026

    B. Braun Medical Recalls Spinal Anesthesia Kits Due to Bupivacaine Hydrochloride Issues

    Braun Medical is recalling convenience kits that contain Bupivacaine Hydrochloride in Dextrose Injection due to safety concerns.

    View detail
  2. signalJun 20, 2026

    Draeger Issues Correction for A350 and A350XL Anesthesia Machines Due to Ventilator Failure Risk

    Draeger, Inc. is correcting additional anesthesia workstations due to a manufacturing error that may lead to ventilator failure.

    View detail
  3. signalJul 23, 2026

    Zydus Pharms receives AP status for Dexmedetomidine Hydrochloride ANDA206798

    Zydus Pharms has received an Abbreviated New Drug Application (ANDA) approval status for Dexmedetomidine Hydrochloride.

    View detail
  4. signalJul 18, 2026

    FDA Accepts Supplement Application for Rocuronium Bromide by Fresenius Kabi

    The FDA has accepted a supplemental application for Rocuronium Bromide submitted by Fresenius Kabi.

    View detail
  5. regulatoryJul 18, 2026

    FDA AP — ARGATROBAN (SUPPL)

    Application NDA201811. Sponsor: FRESENIUS KABI USA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ARGATROBAN.

    View detail
  6. regulatoryJul 18, 2026

    FDA AP — LEVOTHYROXINE SODIUM (SUPPL)

    Application NDA202231. Sponsor: FRESENIUS KABI USA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: LEVOTHYROXINE SODIUM.

    View detail
  7. regulatoryJul 18, 2026

    IND Application Reporting: IND Safety Reports

    This webpage provides an overview of investigational new drug application (IND) safety reporting requirements for sponsors set forth in 21 CFR 312.32 and additional resources, including FDA guidances, related to these requirements.

    View detail
  8. regulatoryJul 18, 2026

    Investigational New Drug (IND) Application

    Get to know the investigational new drug application (IND). This includes the types, laws and regulations, and emergency use of INDs.

    View detail
  9. insightJul 17, 2026

    B. Braun's Recall of Bupivacaine Hydrochloride Kits Signals Regulatory and Competitive Risks

    The recall of B. Braun's spinal anesthesia kits due to safety concerns poses significant risks to the company's market position and reputation. This situation necessitates a thorough investigation to understand the implications for product safety and regulatory compliance. Regulatory context from FDA (FDA AP — BUPIVACAINE HYDROCHLORIDE (ORIG)) supports the near-term read. Assessment grounded in 20 ranked evidence items (5 high-relevance).

    View detail
  10. insightJul 1, 2026

    Hospira's Lidocaine Hydrochloride Approval Enhances Competitive Position in Anesthesia

    The FDA's grant of Abbreviated New Drug Application (ANDA) approval status for Lidocaine Hydrochloride by Hospira is significant as it may strengthen Hospira's competitive position in the local anesthetic market. Companies with similar products should reassess their strategies in light of this development. Regulatory context from FDA (FDA AP — LIDOCAINE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 16 ranked evidence items (8 high-relevance).

    View detail
  11. insightJun 23, 2026

    FDA Approval of Succinylcholine Chloride: New Competitive Dynamics in Neuromuscular Blockers

    The FDA's approval of STERISCIENCE's generic Succinylcholine Chloride introduces a new competitor in the neuromuscular blocker market. This could lead to increased price competition and impact market share for existing products in this therapeutic area. Regulatory context from FDA (FDA AP — SUCCINYLCHOLINE CHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 5 ranked evidence items (3 high-relevance).

    View detail
  12. insightJun 22, 2026

    Medline's Bupivacaine Recall: Strategic Risks and Opportunities in Anesthesia Market

    The recall of Medline's convenience kits containing Huons Bupivacaine Hydrochloride raises safety concerns that could undermine customer trust and impact market share in the anesthesia segment. Portfolio teams need to evaluate the potential revenue implications and develop strategies to address customer concerns and mitigate losses. Regulatory context from FDA (Convenience Kit Correction: Medline Issues Correction for Kits Containing Huons Bupivacaine Hydrochloride in Dextrose Injection, USP) supports the near-term read. Assessment grounded in 22 ranked evidence items (5 high-relevance).

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Executive insights surface 6 risk-calibrated assessments for portfolio review. 89 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 1 companies with active signal exposure for competitive and portfolio shifts.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA AP — ARGATROBAN (SUPPL)

    66%

    Application NDA201811. Sponsor: FRESENIUS KABI USA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ARGATROBAN.

    Source: FDA

    View evidence

  • FDA AP — LEVOTHYROXINE SODIUM (SUPPL)

    66%

    Application NDA202231. Sponsor: FRESENIUS KABI USA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: LEVOTHYROXINE SODIUM.

    Source: FDA

    View evidence

  • IND Application Reporting: IND Safety Reports

    66%

    This webpage provides an overview of investigational new drug application (IND) safety reporting requirements for sponsors set forth in 21 CFR 312.32 and additional resources, including FDA guidances, related to these requirements.

    Source: FDA

    View evidence

  • Investigational New Drug (IND) Application

    66%

    Get to know the investigational new drug application (IND). This includes the types, laws and regulations, and emergency use of INDs.

    Source: FDA

    View evidence

  • FDA AP — ROCURONIUM BROMIDE (SUPPL)

    66%

    Application NDA217472. Sponsor: FRESENIUS KABI USA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ROCURONIUM BROMIDE.

    Source: FDA

    View evidence

  • Other | Cancer Accelerated Approvals

    66%

    This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been granted for supportive care products and changes to dosing or formulation.

    Source: FDA

    View evidence

  • B. Braun's Recall of Bupivacaine Hydrochloride Kits Signals Regulatory and Competitive Risks

    57%

    The recall of B. Braun's spinal anesthesia kits due to safety concerns poses significant risks to the company's market position and reputation. This situation necessitates a thorough investigation to understand the implications for product safety and regulatory compliance. Regulatory context from FDA (FDA AP — BUPIVACAINE HYDROCHLORIDE (ORIG)) supports the near-term read. Assessment grounded in 20 ranked evidence items (5 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Hospira's Lidocaine Hydrochloride Approval Enhances Competitive Position in Anesthesia

    69%

    The FDA's grant of Abbreviated New Drug Application (ANDA) approval status for Lidocaine Hydrochloride by Hospira is significant as it may strengthen Hospira's competitive position in the local anesthetic market. Companies with similar products should reassess their strategies in light of this development. Regulatory context from FDA (FDA AP — LIDOCAINE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 16 ranked evidence items (8 high-relevance).

    Source: Humanexa Insight

    View evidence

  • FDA Approval of Succinylcholine Chloride: New Competitive Dynamics in Neuromuscular Blockers

    68%

    The FDA's approval of STERISCIENCE's generic Succinylcholine Chloride introduces a new competitor in the neuromuscular blocker market. This could lead to increased price competition and impact market share for existing products in this therapeutic area. Regulatory context from FDA (FDA AP — SUCCINYLCHOLINE CHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 5 ranked evidence items (3 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Medline's Bupivacaine Recall: Strategic Risks and Opportunities in Anesthesia Market

    56%

    The recall of Medline's convenience kits containing Huons Bupivacaine Hydrochloride raises safety concerns that could undermine customer trust and impact market share in the anesthesia segment. Portfolio teams need to evaluate the potential revenue implications and develop strategies to address customer concerns and mitigate losses. Regulatory context from FDA (Convenience Kit Correction: Medline Issues Correction for Kits Containing Huons Bupivacaine Hydrochloride in Dextrose Injection, USP) supports the near-term read. Assessment grounded in 22 ranked evidence items (5 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Emerging Trends in Anesthesia: Ketamine, Bupivacaine, and Opioid-Free Strategies

    63%

    This study could significantly influence anaesthesia practices by validating ketamine's role as an adjunct therapy, potentially altering the competitive landscape for anaesthetic agents. A successful outcome may lead to revised clinical guidelines and increased adoption of ketamine in anaesthesia protocols. Assessment grounded in 17 ranked evidence items (8 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Draeger Faces Competitive Pressure Amid Anesthesia Machine Safety Concerns

    56%

    The correction of Draeger's anesthesia machines due to a high-severity ventilator failure risk poses significant reputational and competitive challenges. This situation necessitates close monitoring of Draeger's market position and competitor responses to assess potential shifts in market dynamics. Regulatory context from FDA (Western Mixers Produce & Nuts Issues Allergy Alert on Undeclared Peanuts in First Street Brand, Dark Chocolate Raisins) supports the near-term read. Assessment grounded in 23 ranked evidence items (5 high-relevance).

    Source: Humanexa Insight

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • B. Braun Medical Recalls Spinal Anesthesia Kits Due to Bupivacaine Hydrochloride Issues

    Safety Signal

  • Draeger Issues Correction for A350 and A350XL Anesthesia Machines Due to Ventilator Failure Risk

    Safety Signal

  • Zydus Pharms receives AP status for Dexmedetomidine Hydrochloride ANDA206798

    Regulatory Approval

  • FDA Accepts Supplement Application for Rocuronium Bromide by Fresenius Kabi

    Regulatory Approval

  • FDA Grants Approval for Propofol ANDA220857 by Anthea Pharma

    Regulatory Approval

  • FDA Submission Update for Sugammadex by Tamarang SA

    Regulatory Approval

  • Trial on Low-Dose Remimazolam for Emergence Agitation in Oral Surgery

    Trial Update

  • FDA Accepts Supplemental NDA for Dexmedetomidine Hydrochloride

    Regulatory Approval

Insights

  • B. Braun's Recall of Bupivacaine Hydrochloride Kits Signals Regulatory and Competitive Risks

    Anesthesia · Injectable

  • Hospira's Lidocaine Hydrochloride Approval Enhances Competitive Position in Anesthesia

    Anesthesia · Local Anesthetic

  • FDA Approval of Succinylcholine Chloride: New Competitive Dynamics in Neuromuscular Blockers

    Anesthesia · Neuromuscular Blocker

  • Medline's Bupivacaine Recall: Strategic Risks and Opportunities in Anesthesia Market

    Anesthesia · Local Anesthetics

  • Emerging Trends in Anesthesia: Ketamine, Bupivacaine, and Opioid-Free Strategies

    Anesthesia · Ketamine

  • Draeger Faces Competitive Pressure Amid Anesthesia Machine Safety Concerns

    Anesthesia · Medical Devices

Companies

  • Anthea Pharma

    2 signals

Assets

  • Hospira
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.